"Industrial marijuana concept stock" returns to Tonghua Jinma and Fu'an pharmaceutical industry

The weather is getting warmer, and the "industrial marijuana concept unit", which had just been doused with cold water two or three days ago, seems to be coming back to life Recently, Tonghua Jinma announced that the company will sign the industrial cannabis cooperation project agreement with Jilin Academy of Agricultural Sciences and Erdaojiang District People's Government of Tonghua city to explore the breeding, cultivation and product research and development of industrial cannabis Coincidentally, in the morning of April 1, Fuan pharmaceutical also announced that it had signed a "cooperation intention agreement" with red realty LLC, golden way investor, LLC of the United States The company has technical advantages in the field of drug R & D and production, and intends to carry out plant drug R & D and consumer industrial chain layout in the field of industrial marijuana The partner has a mature industrial marijuana planting base, processing equipment and sales channels in Las Vegas, Nevada, and intends to introduce modern pharmaceutical technology for industrial upgrading On April 1, the industrial cannabis sector as a whole rose 3.46% There are 34 companies involved in the section, with the exception of Dezhan health and St galaxy's decline, others have increased to varying degrees As of 3pm, Tonghua Jinma, Fu'an pharmaceutical, Shunhao shares and Huaren pharmaceutical were up and down The speculation for more than two consecutive months can be said to be very stable, even many enterprises not in the sector have not been spared, only because the business is related to the word "Ma"..... All belt "hemp", all press "industry hemp" processing! Photo source: daily financial news domestic industrial marijuana cultivation policy opening up is speeding up Although industrial marijuana stocks are noisy, they do have great use value According to the data, cannabis is a well-known drug Because of its hallucinogenic ingredient THC, it was once listed as one of the three drugs alongside heroin and cocaine by the United Nations Convention on drugs control, and it was also listed as a restricted drug by the United Nations Commission on narcotic drugs However, the THC values of the industrial marijuana that we have mentioned are all lower than 0.3%, which does not have the value of drug use On the contrary, it has great use value and can be applied to at least textile, papermaking, food, medicine, health and other fields Therefore, industrial marijuana has been sought after by many capital markets The reason why we see many pharmaceutical companies in the industrial hemp sector is that another major component of hemp, cannabis bisphenol (CBD), can not only treat the hallucinogenic symptoms brought by tetrahydrocannabinol, but also has a huge therapeutic value of sedation, anti-inflammatory, anti epilepsy and even tumor treatment From the beginning of 2019 to now, A-share listed pharmaceutical companies including Longjin pharmaceutical, Kangenbei, Huaren pharmaceutical, Tonghua Jinma, etc are all laying out the industrial marijuana cultivation market, and their share prices are also extremely hot At present, the process of policy opening to industrial marijuana is also speeding up in China Yunnan is the only province that allows and supervises industrial marijuana in the form of laws and regulations, while Heilongjiang and Jilin gradually refer to the management regulations of industrial marijuana issued by Yunnan Province Photo source: the first financial medical marijuana is still under the control of "drug marijuana law" Although the cannabis bisphenol (CBD) in marijuana has great medicinal potential and value, the laws and regulations on drug control still apply According to the 21st century economic report, China's supervision of industrial marijuana is very strict Up to now, there are more than 30 enterprises with industrial marijuana planting license in China, but only four enterprises with flower and leaf processing license are hansu biology, hankang biology, Hansen and baiou biology As the parent company of Yunnan hansu biological Co., Ltd., hemp group is a legal investment group in China with the whole industrial chain layout of industrial and medical marijuana and the direction of biopharmaceutical Hua Zhendong, deputy director of the drug laboratory of the drug control information technology center of the Ministry of public security, explained in an interview with China drug control news recently, "At present, except for the industrial marijuana for obtaining fiber and seeds, the marijuana plants for other purposes are under control and must be approved by the competent authorities before planting, and the planting enterprises need to plant according to the annual planting plan and report the planting situation regularly In some areas of our country, the industrial marijuana that is allowed to be planted is the marijuana variety with the total content of THC less than 0.3% which has been bred through scientific screening However, the content of active cannabinoids is higher in tender leaves and flower buds, and the content of tetrahydrocannabinol produced in the process of extraction is often higher than 0.3% In the regulations of Yunnan Province on the license of industrial marijuana cultivation and processing, it is specified that the products with tetrahydrocannabinol content higher than 0.3% extracted from the industrial hemp leaves shall be subject to the laws and regulations on drug control Therefore, even if the industrial hemp is planted, when it is used to extract cannabis diphenol, the relevant enterprises still need to apply according to the control requirements of the drug cannabis, and the production can only be carried out after the approval is obtained, so as to prevent the high content of tetrahydrocannabinol, which can be used as the illegal channel of cannabis extraction and logistics " Market regulation has not been relaxed either Recently, the office of the National Drug Control Commission has issued "notice on strengthening the control of industrial marijuana" According to the notice, the 1961 Convention stipulates that industrial marijuana is limited to fibers and seeds, and the cultivation of other uses is excluded It also states that China has never approved industrial marijuana for medical use and food addition, and that all regions should strictly abide by the regulations At 10 a.m on April 1, the National Drug Control Commission also held a press conference in the press release Office of the Information Office of the State Council At the meeting, Liu Yuejin, deputy director of the National Drug Control Commission and anti-terrorism Commissioner of the Ministry of public security, also made it clear: at present, under the premise of legalizing cannabis in many countries, China will more strictly strengthen the supervision of "industrial cannabis", block loopholes in all aspects, and improve various management systems.